UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.

Agustí, A; Edwards, LD; Rennard, SI; MacNee, W; Tal-Singer, R; Miller, BE; Vestbo, J; ... Evaluation of COPD Longitudinally to Identify Predictive Surroga; + view all (2012) Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One , 7 (5) , Article e37483. 10.1371/journal.pone.0037483. Green open access

[thumbnail of 1382030.pdf]
Preview
PDF
1382030.pdf

Download (405kB)

Abstract

Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552).

Type: Article
Title: Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1371/journal.pone.0037483
Publisher version: http://dx.doi.org/10.1371/journal.pone.0037483
Language: English
Additional information: © 2012 Agustí et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The study was sponsored by GlaxoSmithKline. A Steering Committee and a Scientific Committee comprised of ten academics and six representatives of the sponsor developed the original study design and concepts, the plan for the current analyses, approved the statistical plan, had full access to the data, and were responsible for decisions regarding publication. The study sponsor did not place any restrictions on statements made in the final paper. BRC: Received consulting fees from Altana, AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline; speaking fees from Altana, AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline; and grant support from Boehringer-Ingelheim and GlaxoSmithKline. NL, JY, RT-S, BEM, CC, RJM and LDE: Full-time employees of GlaxoSmithKline and hold stock or stock options in GlaxoSmithKline. PB: Received lecture fees from AstraZeneca, GlaxoSmithKline and NycoMed; has participated in clinical research studies sponsored by GlaxoSmithKline, Pfizer and Boehringer-Ingelheim; is currently member of the Steering Committee and the Scientific Committee of the ECLIPSE study which is sponsored by GlaxoSmithKline PC: Received fees for serving on advisory boards for GlaxoSmithKline, AstraZeneca, Nycomed, Novartis and Boehringer Ingelheim, for expert testimony for Forest/Nycomed, and has received speaker fees from GlaxoSmithKline and Nycomed; has received travel assistance from GlaxoSmithKline to attend ECLIPSE study meetings and from Boehringer Ingelheim to attend a scientific conference. HC: Received an honorarium for serving on the steering committee for the ECLIPSE project for GlaxoSmithKline; was the co-investigator on two multi-center studies sponsored by GlaxoSmithKline and has received travel expenses to attend meetings related to the project; has three contract service agreements with GlaxoSmithKline to quantify the CT scans in subjects with COPD and a service agreement with Spiration Inc to measure changes in lung volume in subjects with severe emphysema; was the co-investigator (D Sin PI) on a Canadian Institutes of Health – Industry (Wyeth) partnership grant; has received a fee for speaking at a conference and related travel expenses from AstraZeneca (Australia); was the recipient of a GSK Clinical Scientist Award (06/2010-07/2011). DAL: Received grant support, honoraria and consultancy fees from GlaxoSmithKline. WM: Received travel assistance from GlaxoSmithKline to attend ECLIPSE study meetings. SR: Received fees for serving on advisory boards, consulting or honoraria from Almirall, APT Pharma, Aradigm, Argenta, AstraZeneca, Boehringer Ingelheim, Chiesi, Dey, Forest, GlaxoSmitkKlein, HoffmanLaRoche, MedImmune, Mpex, Novartis, Nycomed, Oriel, Otsuka, Pearl, Pfizer, Pharmaxis, Merck and Talecris. ES: Received an honorarium for a talk on COPD genetics, grant support for two studies of COPD genetics, and consulting fees from GlaxoSmithKline; honoraria for talks and consulting fees from AstraZeneca. JV: Received fees for serving on advisory boards for GlaxoSmithKline, AstraZeneca, Nycomed and Boehringer Ingelheim, and has received speaker fees from GlaxoSmithKline, AstraZeneca, Pfizer, Boehringer-Ingelheim, Chiesi, Novartis and Nycomed; has received travel assistance from GlaxoSmithKline to attend ECLIPSE study meetings; his wife has previously worked in pharmaceutical companies, including GSK and AstraZeneca. EW: Serves on an advisory board for Nycomed; has received lecture fees from GlaxoSmithKline, AstraZeneca and Novartis, and has received research grants from GlaxoSmithKline and AstraZeneca. AA: Received travel assistance from GlaxoSmithKline to attend ECLIPSE study meetings and honorarium for speaking at conferences and participating in advisory boards from Almirall, Astra-Zeneca, Boheringer-Ingelheim, Chiesi, Esteve, GSK, Medimmune, Novartis, Nycomed, Pfizer, Roche and Procter & Gamble.
Keywords: Biological Markers, C-Reactive Protein, Cohort Studies, Cross-Sectional Studies, Fibrinogen, Humans, Interleukin-6, Interleukin-8, Leukocyte Count, Phenotype, Pulmonary Disease, Chronic Obstructive, Questionnaires, Smoking, Spirometry, Systemic Inflammatory Response Syndrome, Tumor Necrosis Factor-alpha
UCL classification: UCL
UCL > Provost and Vice Provost Offices > VP: Health
URI: https://discovery.ucl.ac.uk/id/eprint/1382030
Downloads since deposit
331Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item